Epizyme (NASDAQ:EPZM) was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating in a research note issued on Friday, February 16th.
Several other equities research analysts have also commented on the stock. Roth Capital assumed coverage on shares of Epizyme in a research note on Thursday, February 1st. They issued a “buy” rating and a $24.00 price objective for the company. Jefferies Group reiterated a “buy” rating and issued a $25.00 price objective on shares of Epizyme in a research note on Wednesday, January 24th. HC Wainwright restated a “buy” rating and set a $25.00 price target on shares of Epizyme in a research note on Thursday, November 2nd. Cann restated a “buy” rating and set a $26.00 price target on shares of Epizyme in a research note on Thursday, November 2nd. Finally, Oppenheimer set a $26.00 price target on shares of Epizyme and gave the stock a “buy” rating in a research note on Tuesday, December 12th. Two analysts have rated the stock with a sell rating, one has given a hold rating and thirteen have given a buy rating to the company. Epizyme presently has a consensus rating of “Buy” and an average price target of $23.33.
Shares of Epizyme (EPZM) traded up $0.60 on Friday, reaching $19.65. 551,512 shares of the company’s stock were exchanged, compared to its average volume of 413,346. The company has a market capitalization of $1,360.00, a PE ratio of -15.12 and a beta of 2.00. Epizyme has a twelve month low of $9.30 and a twelve month high of $21.40.
In other news, COO Matthew Ros sold 72,264 shares of the firm’s stock in a transaction on Monday, February 5th. The shares were sold at an average price of $16.63, for a total transaction of $1,201,750.32. Following the sale, the chief operating officer now owns 74,867 shares in the company, valued at approximately $1,245,038.21. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 25.20% of the company’s stock.
Large investors have recently modified their holdings of the stock. Fox Run Management L.L.C. purchased a new position in Epizyme in the 3rd quarter worth $223,000. JGP Global Gestao de Recursos Ltda. purchased a new position in Epizyme in the 3rd quarter worth $292,000. Teacher Retirement System of Texas purchased a new position in Epizyme in the 4th quarter worth $202,000. Bailard Inc. purchased a new position in Epizyme in the 4th quarter worth $251,000. Finally, MetLife Investment Advisors LLC purchased a new position in Epizyme in the 4th quarter worth $263,000. Institutional investors own 86.09% of the company’s stock.
Epizyme Company Profile
Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).
Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.